PharmaZell Continues API Expansion in India

PharmaZell GmbH has expanded its manufacturing capabilities in India. The company has completed construction of a cGMP kilo-lab at its R&D center in Vizag, India. This follows two other recent expansions in India. In 2007, PharmaZell built a commercial production plant in Vizag, India to produce the API, Mesalamine. In 2008, PharmaZell continued expanding in Vizag by building an R&D facility that now employs approximately 35 chemists focused on chemical route and process development, analytical R&D and small scale synthesis.

The company also expanded its European base in 2007 by acquiring a fully integrated development and commercial production site from Sandoz in Copenhagen. The site in Denmark has a focus on controlled substances, and its scientists have expertise in lab development, pilot plant and commercial manufacturing under cGMP.

“In the past three years PharmaZell has had three expansions in India while growing by acquisition in Europe. We have continued to grow our manufacturing capacity and expand our services to the pharmaceutical and biotechnology industries. We believe that our strong revenue growth and diverse customer base is positioning our company as a significant API manufacturer and service provider,” said Wolfgang Burger, Ph.D., managing partner of PharmaZell.